Revenue segments as reported by the company.

Pharmacy revenues

Premiums

Fees and other revenues

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Pharmacy and other service costs

Medical costs and other benefit expenses

Selling, general and administrative expenses

Amortization of acquired intangible assets

Special items

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cigna

Express Scripts is a company that provides integrated pharmacy benefit management services including network-pharmacy claims processing; home delivery pharmacy services; specialty pharmacy benefit management, through its subsidiary Accredo; benefit-design consultation; drug-utilization review; formulary management; and medical and drug data analysis services to manage drug plans for health plans, self-insured employers and government agencies (both as administrator of employee benefits and public assistance programs). Express Scripts also offers pharmacy benefit management services for workers' compensation insurance programs. The program is accredited by URAC, the nation's largest accrediting body for pharmacy benefit management companies. The company processes pharmaceutical claims for members through a network of retail pharmacies. Its own automated pharmacies dispense long-term, chronic medications-like those for diabetes or heart disease-directly to members by home delivery.

Express Scripts

The Cigna Group is a global health company, which engages in the provision of global health services. It operates through the following segments: Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate. The Evernorth Health Services segment partners with health plans, employers, governmental organizations, and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. The Cigna Healthcare segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. The Other Operations segment consists of the remainder of business operations, which includes certain ongoing businesses and exited businesses. The Corporate segment refers to net interest expense, certain litigation matters, expense associated with frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments. The company was founded in 1792 and is headquartered in Bloomfield, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cigna posts strong Q4 earnings, eyes growth in specialized services

Cigna delivered strong financial results in Q4 2022, with robust revenue growth and operational performance across key business segments.
While facing challenges such as margin pressures and potential disenrollment, Cigna is well-positioned to capitalize on growth opportunities in 2023.
Strategic partnerships, customer-focused strategies, and financial discipline underscore Cigna's commitment to sustainable growth and shareholder value creation.
Investments in innovation, care coordination, and market expansion signal a proactive approach to navigating industry dynamics and driving future success.

Cigna reports robust Q1 earnings, eyes growth amid challenges

Cigna's Q1 2023 showcased strong financials, growth in key segments, and increased outlook.
Challenges include economic softening impact and margin expectations for the year.
Opportunities lie in customer relationships, innovation, and market-specific strategies.
Overall, Cigna remains confident in delivering on its financial and growth targets.

Cigna reports robust Q2 results, eyes growth through innovation

Cigna's Q2 2023 performance was strong, with revenue growth, customer expansion, and technological advancements driving positive outcomes.
While facing challenges like disenrollment and risk adjustment payables, Cigna is leveraging strengths in technology and cross-selling for growth.
Opportunities lie in partnerships like VillageMD, continued innovation, and strategic bidding strategies for future growth.
Overall, Cigna remains confident in delivering on adjusted EPS outlook for 2023 and 2024, with a focus on innovation and growth.

Cigna surpasses Q3 expectations, eyes $28 EPS in 2024

Cigna's Q3 performance exceeded expectations, driven by strong revenue and EPS growth across key business segments.
Strategic focus on innovation, affordability, and client partnerships positions Cigna well for future growth and value creation.
Challenges in margin expectations and enrollment declines require proactive management and strategic decision-making.
Opportunities lie in continued growth projections, strategic investments, and enhancing healthcare affordability and accessibility.

Cigna reports robust Q4 performance, eyes growth amid strategic changes

Cigna Group's Q4 2023 Earnings Call highlighted strong financial performance, leadership changes, and strategic decisions. Analyst inquiries focused on growth drivers, market outlook, and internal healthcare spend management. The outlook for 2024 includes expectations of solid adjusted EPS, revenue growth, and operating cash flow.

Cigna surpasses Q1 expectations, eyes growth through AI and biosimilars

Cigna's Q1 performance exceeded expectations, driven by strong revenue and EPS figures.
Despite challenges like noncash losses and disruptions, Cigna's strategic strengths in AI, biosimilars, and value-based care position it well for growth.
Opportunities in AI-driven healthcare solutions, biosimilar expansions, and strategic M&A offer avenues for future growth.
Cigna's focus on precision care solutions and client outcomes showcases its commitment to innovation and efficiency.

Cigna (CI) posts robust Q2 results, eyes biosimilar growth

Cigna (CI) reports strong Q2 financial results driven by Evernorth Health Services and Express Scripts' innovative programs.
Focus on affordability, access, and behavioral health services propels growth in U.S. employer business.
Challenges include navigating healthcare cost pressures and ensuring fair pricing negotiations.
Opportunities lie in biosimilar growth, sustainable revenue outlook, and strategic Medicare Advantage business sale.

Cigna reports robust Q3 earnings, eyes growth opportunities in 2025

Cigna's Q3 earnings call highlighted strong financial performance, strategic focus on shareholder value, and challenges in specialty drugs and cost trends. The company is optimistic about opportunities in 2025 and remains committed to delivering shareholder value through strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ABM Industries

Archer-Daniels-Midland Company

ArcBest

Caleres

We believe, broker-friendly stocks like ArcBest (ARCB), Archer Daniels (ADM), ABM Industries (ABM), Caleres (CAL) and Cigna (CI) should be on an investor's watchlist.

5 Stocks to Watch for Following Recent Broker Upgrade

Ball

Domino's Pizza

Goldman Sachs

Home Depot

Humana

Lowe's

Mastercard

Starbucks

Sherwin-Williams

Sirius XM Holdings Inc

Skyworks Solutions

Tractor Supply

Visa

I present my top 15 high-growth dividend stocks to consider during the month of April.

My Top 15 High Growth Dividend Stocks For April 2022

APA Corporation

Kite Realty Group

Public Storage

Redwood Trust

Targa Resources

Valero Energy

Webster Financial

The Wall Street firms that we cover here at 24/7 Wall St. all keep a list for their institutional and retail clients of high-conviction stock picks.

8 ‘Strong Buy' Analyst Favorites With Big, Dependable Dividends Are Ideal Q2 Picks

Cigna is currently trading at an attractive valuation.

Cigna Is An Attractive Investment In This Market Environment

Cigna Corp. (CI) expects to buy back more than $7 billion worth of shares in 2022.

Cigna Corp. (CI) Up 7.8% in 3 Months: More Room to Grow?

We think that Cigna stock (NYSE: CI) currently is a better pick compared to UnitedHealth stock (NYSE: UNH) in the healthcare sector, given its comparatively lower valuation and better prospects. UNH stock trades at about 1.6x trailing revenues, compared to just 0.4x for CI stock.

This Health Insurance Company Is A Better Pick Over UnitedHealth Stock

Cigna Corp. ( CI , Financial) has only increased its dividend twice in the last decade, but the first one was a 9,900% increase in 2021 followed by a 12% increase for the upcoming March 24 payment date.

Cigna Is a Future Dividend Growth Superstar

Amphenol

Blackrock Inc

FedEx

Monolithic Power Systems

Charles Schwab

Texas Instruments

I present my top 15 high-growth dividend stocks to consider during the month of March.

My Top 15 High Growth Dividend Stocks For March 2022

Cigna's (CI) shares gain on plans to deploy capital via share buybacks and targeted bolt-on acquisitions, which reflect its financial strength.

Cigna (CI) Unveils '22 Capital Deployment Plans, Shares Up

Health care company Cigna Corp. CI, +3.75% said Monday its board has approved a series of capital deployment moves for 2022, including new share buybacks and strategic investments. The board has approved an additional $6 billion in share buybacks, boosting the company's authorization to $10 billion.

Cigna board adds $6 billion to company's share buyback authorization, boosting it to $10 billion

BLOOMFIELD, Conn., Feb. 28, 2022 /PRNewswire/ -- Global health service company Cigna Corporation (NYSE: CI) today announced a series of capital deployment priorities designed to enhance shareholder value and deliver long-term growth.

Cigna Announces Significant Increase to Share Repurchase Program and Capital Deployment

AbbVie

PepsiCo

Prudential Financial

W. P. Carey

Income investments are great for volatile times, as investors dump technology stocks and seek steady dividends and capital gains. The post 7 High-Yield Blue-Chip Stocks Suitable for Any Retiree appeared first on InvestorPlace.

7 High-Yield Blue-Chip Stocks Suitable for Any Retiree

BLOOMFIELD, Conn., Feb. 23, 2022 /PRNewswire/ -- Global health services company Cigna Corporation (NYSE:CI) announced today that Brian Evanko, executive vice president and chief financial officer, will present at the Barclays Global Healthcare Conference on March 16, 2022 in Miami, FL.

Cigna Corporation Announces Appearance at the Barclays Global Healthcare Conference

BLOOMFIELD, Conn., Feb. 18, 2022 /PRNewswire/ -- Cigna Corporation (NYSE: CI), a global health service company, today announced that John Murabito, longtime Chief Human Resources Officer (CHRO) and current Chief Administrative Officer (CAO), will retire on April 1.

Cigna Corporation Announces Cynthia Ryan as Chief Human Resources Officer as Longtime CHRO John Murabito Retires

BLOOMFIELD, Conn. and NEW YORK, Feb. 15, 2022 /PRNewswire/ -- Evernorth, the health services business of Cigna Corporation (NYSE: CI), and Monument announced that they are making it easier for millions of customers to access alcohol use disorder (AUD) treatment through Monument's virtual platform.

With Heavy Alcohol Use Increasing, Evernorth Expands Access to Treatment with Monument's Virtual Services

BLOOMFIELD, Conn., Feb. 14, 2022 /PRNewswire/ -- Global health services company Cigna Corporation (NYSE:CI) announced today that Eric Palmer, president and chief executive officer of Evernorth, will present at the Cowen 42nd Annual Health Care Conference on March 7, 2022 through a virtual webcast.

Cigna Corporation Announces Appearance at the Cowen 42nd Annual Health Care Conference

BLOOMFIELD, Conn., Feb. 10, 2022 /PRNewswire/ -- Accredo®, the specialty pharmacy subsidiary of Evernorth, Cigna Corporation's health services business, was awarded URAC's Rare Disease Pharmacy Center of Excellence designation.

Evernorth's Accredo Earns URAC Rare Disease Pharmacy Center of Excellence Designation

Cigna has participated in the rotation from growth to value, but still trades at 10x earnings. The company has been an aggressive buyer of its own stock.

Cigna: 10x Earnings, Aggressive Buybacks, Upside Inevitable

Cigna is a well-run, vertically integrated health insurance provider that's seeing top and bottom line growth.

Cigna: One Of The Best Blue-Chip Bargains For February

Cigna Corporation (CI) CEO David Cordani on Q4 2021 Results - Earnings Call Transcript

Cigna's (CI) fourth-quarter results benefit from strong medical customer growth. A solid outlook for 2022 when compared to the 2021 level remains noteworthy.

Cigna (CI) Q4 Earnings Beat on Robust Cigna Healthcare Unit

Cigna Corp CI reports Q4 total revenues of $45.68 billion, +9.6% Y/Y, ahead of the consensus of $43.88 billion. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

Cigna Shares Fall As FY22 Guidance Falls Short Of Consensus; Q4 Profit Of $1.1B

Cigna (CI) delivered earnings and revenue surprises of 1.92% and 3.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Cigna (CI) Q4 Earnings and Revenues Beat Estimates

Shares of Cigna Corp CI, +1.82% slipped 0.9% in premarket trading Thursday, after the health insurer reported both fourth-quarter adjusted profit and revenue that rose above expectations and raised its dividend by 12%, but provided a downbeat outlook. Net income was $1.12 billion, or $3.39 a share, compared with $4.14 billion, or $11.45 a share, in the year-ago period.

Cigna beats profit, revenue expectations and raises dividend, but stock falls

BLOOMFIELD, Conn., Feb. 3, 2022 /PRNewswire/ -- Total revenues for 2021 were $174.1 billion, and adjusted revenues1 for 2021 were $174.1 billion   Shareholders' net income for 2021 was $5.4 billion, or $15.73 per share   Adjusted income from operations2 for 2021 was $7.0 billion, or $20.47 per share   Adjusted income from operations2,3 is projected to be at least $6.95 billion in 2022, or at least $22.40 per share3   Board of Directors declared a 12% increase in the quarterly dividend rate, to $1.12 per share Global health services company Cigna Corporation (NYSE: CI) today reported 2021 results reflecting continued strong business growth aided by the Company's diversified portfolio.

News for Cigna Stock (CI)